⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 1, 2026Transplantation and Cellular Therapy

Population Pharmacokinetic Modeling of Thiotepa in Pediatric and Young Adult HCT Recipients

Jordan Brooks M.A. Hughes Ron J. Keizer Christopher C. Dvorak Janel Long-Boyle

View at Publisher

Ask AI

Bookmark

Share

Key Points

Dosing recommendations for thiotepa are optimized for pediatric and young adult populations, enhancing treatment efficacy.
Key pharmacokinetic parameters were identified in population analysis across multiple patients, improving precision.
The observational analysis utilized pharmacokinetic data from pediatric and young adult hematopoietic cell transplant recipients.
This work highlights the need for tailored dosing strategies in young patients, emphasizing population pharmacokinetic considerations.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Analysis uncovers dosing parameters for thiotepa in pediatric and young adult HCT recipients, suggesting improved care.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Brooks et al. (2026) studied this question.

synapsesocial.com/papers/69a760c8c6e9836116a2dd85 https://doi.org/10.1016/j.jtct.2025.12.153

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD StatusTransplantation and Cellular Therapy · 2026
2Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary OutcomesTransplantation and Cellular Therapy · 2026
3Trends and Disparities in CAR-T Therapy Utilization, Inpatient Mortality, Length of Stay, and Costs in the United States (2017–2022)Transplantation and Cellular Therapy · 2026
4Cytomegalovirus After Autologous Hematopoietic Cell Transplantation: Impact on Outcome and A Personalized Risk-adapted Prevention StrategyTransplantation and Cellular Therapy · 2026
5Clinical trials in graft-versus-host disease: changes in study characteristics, investigated drugs, and endpoints over timeTransplantation and Cellular Therapy · 2026
6Nationwide Centralized Manufacturing and Fresh Distribution of TCRαβ/CD19-DepletedGrafts: A Real-World French ExperienceTransplantation and Cellular Therapy · 2026
7Polyomavirus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Multicenter Retrospective AnalysisTransplantation and Cellular Therapy · 2026
8Lung Complications after Allogeneic Hematopoietic Cell Transplant and Outcomes: Implications Beyond Bronchiolitis Obliterans SyndromeTransplantation and Cellular Therapy · 2026
9A Phase Ib Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy · 2026
10Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regressionTransplantation and Cellular Therapy · 2026

TMore from Transplantation and Cellular Therapy

More from University of California, San Francisco

More from University of California System

More from UCSF Benioff Children's Hospital

More from IDinsight